The Report: Abu Dhabi 2025 will examine the key factors shaping the emirate’s economic growth, with a particular focus on the ...

Muscat: A new report produced by Oxford Business Group (OBG), in partnership with Oman’s Ministry of Commerce, Industry and ...

Press releases distributed by APO Group also benefit from guaranteed publication on 300+ African news websites, as well as international partner services such as Getty Images, Bloomberg, Thomson ...

Japan's Mitsubishi Motors , a junior partner of Nissan Motor , is planning to outsource the production of electric vehicles ...

Nike on Thursday forecast a steeper drop in fourth-quarter revenue than analysts had expected, striking a cautious tone as it ...

Shares of Thomson Reuters Corp. TRI slid 0.77% to C$250.47 Thursday, in what proved to be an all-around negative trading session for the Canadian market, with the S&P/TSX Composite Index GSPTSE ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Thomson Reuters Corporation's ( TSE:TRI ) recent weak earnings report didn't cause a big stock movement. However, we... Thomson Reuters (TSX/Nasdaq: TRI), a global content and technology company ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Eikon Therapeutics is no stranger to eye-popping funding rounds, and the cancer-focused biotech has continued this trend with a $350.7 million series D to fuel its various clinical trials.

The upward trajectory continues for Eikon Therapeutics, which announced that it has raised $351 million to fund various cancer related clinical trials. The Series D funding unveiled Wednesday morning ...